http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Feb 2026 08:47:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./25965509.html si-local-file:///var/storage/secattach/20260209/25965509.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./25965509.html Mon, 09 Feb 2026 08:47:00 -0500 ASMB O.09748574 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./25965509.html si-local-file:///var/storage/secattach/20260209/25965509.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+Farallon+Capital+Partners%2C+L.P./25965509.html Mon, 09 Feb 2026 08:47:00 -0500 ASMB O.09748574 http://www.streetinsider.com/Corporate+News/Gilead+exercises+option+for+Assembly+Bio%27s+herpes+treatment+programs/25767874.html <p>Gilead Sciences Inc. (NASDAQ: GILD) has exercised its option to exclusively license Assembly Biosciences Inc.'s (NASDAQ: ASMB) herpes simplex virus helicase-primase inhibitor programs, including investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes treatment.</p><p>Assembly Biosciences will receive a $35 million payment for the option exercise, which reflects a $45 million option fee minus $10 million in accelerated funding received in December 2024. The transaction stems from a 2023 collaboration agreement between the companies.</p><p>The licensed compounds are designed as once-weekly oral treatments for recurrent genital herpes. Interim Phase 1b data showed both candidates demonstrated antiviral activity and reductions in virus-positive lesions, http://www.streetinsider.com/Corporate+News/Gilead+exercises+option+for+Assembly+Bio%27s+herpes+treatment+programs/25767874.html Mon, 22 Dec 2025 08:02:22 -0500 ASMB GILD http://www.streetinsider.com/Corporate+News/Gilead+exercises+option+for+Assembly+Bio%27s+herpes+treatment+programs/25767874.html <p>Gilead Sciences Inc. (NASDAQ: GILD) has exercised its option to exclusively license Assembly Biosciences Inc.'s (NASDAQ: ASMB) herpes simplex virus helicase-primase inhibitor programs, including investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes treatment.</p><p>Assembly Biosciences will receive a $35 million payment for the option exercise, which reflects a $45 million option fee minus $10 million in accelerated funding received in December 2024. The transaction stems from a 2023 collaboration agreement between the companies.</p><p>The licensed compounds are designed as once-weekly oral treatments for recurrent genital herpes. Interim Phase 1b data showed both candidates demonstrated antiviral activity and reductions in virus-positive lesions, http://www.streetinsider.com/Corporate+News/Gilead+exercises+option+for+Assembly+Bio%27s+herpes+treatment+programs/25767874.html Mon, 22 Dec 2025 08:02:22 -0500 ASMB GILD http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Press+Releases/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html <p class="bwalignc"> <i>– Weekly Oral Helicase-Primase Inhibitor Programs&apos; Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –</i> </p> <p> FOSTER CITY, Calif. &amp; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2023%2Fgilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases&amp;esheet=54382060&amp;newsitemid=20251222410533&amp;lan=en-US&amp;anchor=R%26amp%3BD+collaboration&amp;index=1&amp;md5=ee73b327a0681193d53ad16296795154" shape="rect">R&amp;D collaboration</a>, reinforcing the companies’ commitment to http://www.streetinsider.com/Business+Wire/Gilead+Sciences+Exercises+Option+to+License+Assembly+Biosciences%E2%80%99+Helicase-Primase+Inhibitor+Programs+for+Recurrent+Genital+Herpes/25767790.html Mon, 22 Dec 2025 08:00:00 -0500 A.50204288 ASMB GILD O.00092067 O.09748574 O.54970957 http://www.streetinsider.com/Analyst+PT+Change/Assembly+Biosciences+%28ASMB%29+PT+Raised+to+%2462+at+Jefferies/25720281.html <p>Jefferies analyst Dennis Ding raised the price target on Assembly Biosciences (NASDAQ: ASMB) to $62.00 (from $35.00) while maintaining a Buy rating.</p><p>The analyst comments "ASMB reported (+) HSV data and is planning to move ahead with both assets. For '5366, monthly data had slightly weaker efficacy, which is expected, but gives ASMB commercial optionality. For ‘1179, which came from partner GILD, efficacy was numerically better than '5366 but still generally in line. Key is both had solid efficacy on HSV suppression and now ASMB has two very efficacious orals, which is intriguing, given inexpensive $550M market cap. PT to $62."</p> http://www.streetinsider.com/Analyst+PT+Change/Assembly+Biosciences+%28ASMB%29+PT+Raised+to+%2462+at+Jefferies/25720281.html Wed, 10 Dec 2025 04:53:42 -0500 ASMB http://www.streetinsider.com/Analyst+Comments/Assembly+Biosciences+%28ASMB%29+PT+Raised+to+%2462+at+Jefferies/25720281.html <p>Jefferies analyst Dennis Ding raised the price target on Assembly Biosciences (NASDAQ: ASMB) to $62.00 (from $35.00) while maintaining a Buy rating.</p><p>The analyst comments "ASMB reported (+) HSV data and is planning to move ahead with both assets. For '5366, monthly data had slightly weaker efficacy, which is expected, but gives ASMB commercial optionality. For ‘1179, which came from partner GILD, efficacy was numerically better than '5366 but still generally in line. Key is both had solid efficacy on HSV suppression and now ASMB has two very efficacious orals, which is intriguing, given inexpensive $550M market cap. PT to $62."</p> http://www.streetinsider.com/Analyst+Comments/Assembly+Biosciences+%28ASMB%29+PT+Raised+to+%2462+at+Jefferies/25720281.html Wed, 10 Dec 2025 04:53:42 -0500 ASMB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ASSEMBLY+BIOSCIENCES%2C+++++For%3A+Dec+08/25712539.html si-local-file:///var/storage/secattach/20251208/25712539.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ASSEMBLY+BIOSCIENCES%2C+++++For%3A+Dec+08/25712539.html Mon, 08 Dec 2025 16:18:00 -0500 ASMB O.09748574 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ASSEMBLY+BIOSCIENCES%2C+++++For%3A+Dec+08/25712539.html si-local-file:///var/storage/secattach/20251208/25712539.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ASSEMBLY+BIOSCIENCES%2C+++++For%3A+Dec+08/25712539.html Mon, 08 Dec 2025 16:18:00 -0500 ASMB O.09748574 http://www.streetinsider.com/FDA/Assembly+Biosciences+reports+positive+herpes+drug+trial+results/25712282.html <p>Assembly Biosciences Inc. (NASDAQ: ASMB) reported positive interim results from Phase 1b studies of two experimental herpes simplex virus treatments, ABI-1179 and ABI-5366, according to a company statement.</p> <p>In the ABI-1179 study, the 50 mg weekly oral dose showed a 98% reduction in HSV-2 shedding rate compared to placebo over 29 days, exceeding the company's target of 80%-85% reduction. The treatment also demonstrated a 91% reduction in virologically confirmed genital lesion rate and a greater than 99% reduction in high viral load shedding samples.</p> <p>For ABI-5366 monthly dosing, results showed a 76% reduction in HSV-2 shedding rate and an 88% reduction in http://www.streetinsider.com/FDA/Assembly+Biosciences+reports+positive+herpes+drug+trial+results/25712282.html Mon, 08 Dec 2025 16:05:22 -0500 ASMB http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+Reports+Positive+Interim+Results+from+Phase+1b+Clinical+Studies+of+Long-Acting+Helicase-Primase+Inhibitor+Candidates+ABI-1179+and+ABI-5366+Showing+Reductions+in+Viral+Shedding+Rat/25712256.html <p align="center"><em>– 98% reduction in HSV-2 shedding rate, &gt;99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179,</em><em> exceeding expectations for the study</em> <em>– </em></p> <p align="center"><em>– 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 –</em></p> <p align="center"><em>– Company to hold conference call today at 6 p.m. ET –</em></p> <p>SOUTH SAN FRANCISCO, Calif., Dec. 08, http://www.streetinsider.com/Press+Releases/Assembly+Biosciences+Reports+Positive+Interim+Results+from+Phase+1b+Clinical+Studies+of+Long-Acting+Helicase-Primase+Inhibitor+Candidates+ABI-1179+and+ABI-5366+Showing+Reductions+in+Viral+Shedding+Rat/25712256.html Mon, 08 Dec 2025 16:05:00 -0500 ASMB http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+Reports+Positive+Interim+Results+from+Phase+1b+Clinical+Studies+of+Long-Acting+Helicase-Primase+Inhibitor+Candidates+ABI-1179+and+ABI-5366+Showing+Reductions+in+Viral+Shedding+Rat/25712256.html <p align="center"><em>– 98% reduction in HSV-2 shedding rate, &gt;99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179,</em><em> exceeding expectations for the study</em> <em>– </em></p> <p align="center"><em>– 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 –</em></p> <p align="center"><em>– Company to hold conference call today at 6 p.m. ET –</em></p> <p>SOUTH SAN FRANCISCO, Calif., Dec. 08, http://www.streetinsider.com/Globe+Newswire/Assembly+Biosciences+Reports+Positive+Interim+Results+from+Phase+1b+Clinical+Studies+of+Long-Acting+Helicase-Primase+Inhibitor+Candidates+ABI-1179+and+ABI-5366+Showing+Reductions+in+Viral+Shedding+Rat/25712256.html Mon, 08 Dec 2025 16:05:00 -0500 ASMB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25711124.html si-local-file:///var/storage/secattach/20251208/25711124.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25711124.html Mon, 08 Dec 2025 11:43:00 -0500 ASMB O.09748574 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25711124.html si-local-file:///var/storage/secattach/20251208/25711124.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ASSEMBLY+BIOSCIENCES%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/25711124.html Mon, 08 Dec 2025 11:43:00 -0500 ASMB O.09748574